Aerie Pharma (AERI) PT Lowered to $48 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts AERI Hot Sheet
Price: $15.25 --0%
Rating Summary:
12 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
12 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Needham & Company analyst Serge Belanger lowered the price target on Aerie Pharma (NASDAQ: AERI) to $48.00 (from $54.00) while maintaining a Buy rating ahead of the company's 3Q report.
Needham & Company adjusted 3Q19 sales estimates to $18.3MM (from $20.6MM) to reflect a lower Rx net price. Belanger believes 2019 sales can meet the low end of the $70MM- $80MM guidance range but it will likely require further growth inflection in Nov/Dec as well as improved Rx pricing via the recent price increase.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Stryker (SYK) PT Lowered to $325 at Piper Sandler
- John B. Sanfilippo & Son, Inc. (JBSS) PT Lowered to $79 at Freedom Broker
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
